You are here

JNJ

J&J Drops in Device Sales for 2019 Earnings

J&J Drops in Device Sales for 2019 Earnings

Medical Devices and Diagnostics Industry

Flag link:

Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'

Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'

Fierce Pharma

Flag link:

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Pharmaceutical Business Review

Flag link:

Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

Yahoo/Zacks.com

Flag link:

Johnson & Johnson Gets Punitive Damages in Risperdal Case Reduced to $6.8 Million

Johnson & Johnson Gets Punitive Damages in Risperdal Case Reduced to $6.8 Million

Motley Fool

Flag link:

Why Johnson & Johnson Will Survive its Latest Litigation Wave

Why Johnson & Johnson Will Survive its Latest Litigation Wave

Motley Fool

Flag link:

J&J, RoosterBio and Element Kick Off 2020 with Expansions

J&J, RoosterBio and Element Kick Off 2020 with Expansions

BioSpace

Element Biosciences

Flag link:

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

AP

Flag link:

J&J said to pay more than US$2M in rare talc settlement

J&J said to pay more than US$2M in rare talc settlement

Bloomberg

Flag link:

Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated

Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated

Stat

major depression

Flag link:

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Endpoints

Flag link:

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

Fierce Biotech

Crohn’s disease

Flag link:

If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now

If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now

Motley Fool

Flag link:

J&J Fires up the Surgical Robotics Market with New Verb Deal

J&J Fires up the Surgical Robotics Market with New Verb Deal

Medical Devices and Diagnostics Industry

robotic surgery

Flag link:

Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod

Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod

Fierce Pharma

prostate cancer

Flag link:

Attorney misconduct allegations crop up in Johnson & Johnson, Gilead cases

Attorney misconduct allegations crop up in Johnson & Johnson, Gilead cases

Fierce Pharma

Gilead Sciences

Flag link:

Leukemia rivals try to stay ahead as Merck, Lilly chase

Leukemia rivals try to stay ahead as Merck, Lilly chase

Biopharma Dive

Flag link:

ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients

ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients

Fierce Pharma

Multiple Myeloma

Flag link:

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Pharmaforum

Flag link:

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

Seeking Alpha

Flag link:

Pages